Do glucagonomas always produce glucagon?
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Do glucagonomas always produce glucagon?
Forlagets udgivne version, 1,87 MB, PDF-dokument
Pancreatic islet α-cell tumours that overexpress proglucagon are typically associated with the glucagonoma syndrome, a rare disease entity characterised by necrolytic migratory erythema, impaired glucose tolerance, thromboembolic complications and psychiatric disturbances. Paraneoplastic phenomena associated with enteric overexpression of proglucagon-derived peptides are less well recognized and include gastrointestinal dysfunction and hyperinsulinaemic hypoglycaemia. The diverse clinical manifestations associated with glucagon-expressing tumours can be explained, in part, by the repertoire of tumorally secreted peptides liberated through differential post-translational processing of tumour-derived proglucagon. Proglucagon-expressing tumours may be divided into two broad biochemical subtypes defined by either secretion of glucagon or GLP-1, GLP-2 and the glucagon-containing peptides, glicentin and oxyntomodulin, due to an islet α-cell or enteroendocrine L-cell pattern of proglucagon processing, respectively. In the current review we provide an updated overview of the clinical presentation of proglucagon-expressing tumours in relation to known physiological actions of proglucagon-derived peptides and suggest that detailed biochemical characterisation of the peptide repertoire secreted from these tumours may provide new opportunities for diagnosis and clinical management.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Bosnian Journal of Basic Medical Sciences |
Vol/bind | 16 |
Udgave nummer | 1 |
Sider (fra-til) | 1-7 |
Antal sider | 7 |
ISSN | 1512-8601 |
DOI | |
Status | Udgivet - 1 feb. 2016 |
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 156084823